192P ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations by Saw, P.L.S., Tan, G.S., Tan, A., Lai, G., Tan, W.C., Tan, E.H., Ang, M-K., Lim, D.W-T., Kanesvaran, R., Ng, Q.S., Jain, A., Tan, W.L., Rajasekaran, T., Chan, J., Teh, Y.L., Tan, S.H., Lim, T.K.H., Tan, D.S.W.

Get full text

112P Sequencing post osimertinib with liquid biopsy to assess TKI resistance in patients with advanced EGFR-mutant NSCLC (SOLITAIRE study) by Tan, W.L., Ang, S.F., Chan, Z.L., Teng, R.S.Y., Lau, D.P., Tan, A., Lai, G., Saw, P.L.S., Seet, A., Tan, W.C., Chan, J., Teh, Y.L., Tan, S.H., Jain, A., Kanesvaran, R., Ang, M-K., Ng, Q.S., Lim, D.W-T., Tan, D.S.W.

Get full text

230P Clinicopathologic and molecular features of STK11-mutated NSCLC by Saw, P.L.S., Pang, M., Tan, G.S., Sim, N.L., Patteri, C., Lai, G., Tan, A., Chan, J., Tan, W.L., Ng, Q.S., Ang, M-K., Lim, D.W-T., Lim, T.K.H., Skanderup, A., Tan, D.S.W.

Get full text

85O Low-pass whole genome sequencing (lpWGS) to quantify circulating tumor DNA (ctDNA) burden as a pharmacodynamic response biomarker in patients on early phase trials by Tan, A.C., Guo, Y.A., Rahman, C.R., Tan, T.J.Y., Saw, P.L.S., Lam, J., Tai, D., Lim, D.W-T., Chang, E.W.Y., Chan, J., Tan, W.C., Tan, S., Boey, M., Carolyn, C., Carrie, H.C., Yeo, J.C., Tan, I., Ng, M.C.H., Tan, D.S.W., Skanderup, A.

Get full text